Stockreport

The Bull Case For Castle Biosciences (CSTL) Could Change Following Surging Test Volumes And Raised 2025 Outlook [Yahoo! Finance]

Castle Biosciences, Inc. - Common stock  (CSTL) 
Last castle biosciences, inc. - common stock earnings: 3/10 04:05 pm Check Earnings Report
PDF volumes for DecisionDx-Melanoma and TissueCypher and expecting 2025 revenue to exceed US$340 million, above prior guidance. The company also launched its AdvanceAD-Tx [Read more]